Navigation Links
Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin
Date:11/25/2008

SOUTH SAN FRANCISCO, Calif., Nov. 25 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, announced today that it will be exploring strategic alternatives for its preclinical research programs in order to allow the Company to focus its resources on the clinical development of picoplatin, its lead product candidate, and to support the initial commercialization of picoplatin in the treatment of small cell lung cancer, currently targeted for 2010.

"We are committed to focusing our resources on the development and commercialization of picoplatin, as is underscored by the commercial supply agreement with Baxter Oncology GmbH that we announced yesterday. We believe that picoplatin is a platform product with the potential to treat multiple tumor types. This is supported by recent positive Phase 2 data in ongoing clinical trials in colorectal and prostate cancer," said Jerry McMahon, Ph.D., CEO and chairman of Poniard. "In addition, our ongoing Phase 3 registration trial in small cell lung cancer is on track, with the potential to bring picoplatin to market in that indication in 2010."

The company also announced that the employment of David Karlin, M.D., senior vice president, clinical development, was terminated on November 21. The termination was based on the Company's determination that it no longer required the services of Dr. Karlin. Dr. Karlin's responsibilities will be assumed by Robert De Jager, M.D., chief medical officer of Poniard.

Separately, Caroline Loewy, chief financial officer, provided written notice of her resignation from the Company to pursue another employment opportunity. Ms. Loewy's last day of employment will be November 28. Dr. McMahon and Ronald Martell, president and chief operating officer, wi
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
10. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
11. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... PITTSBURGH , July 27, 2015  Mylan N.V. (NASDAQ: ... extraordinary general meeting of shareholders in connection with its proposed ... at the Okura Hotel Amsterdam on Friday, Aug. 28, 2015 ... Among other agenda items at the extraordinary general meeting, Mylan ... 2:107a of the Dutch Civil Code, of the acquisition of ...
(Date:7/27/2015)... 27, 2015  The fairness of the proposed acquisition ... Jude Medical ("St. Jude") is the subject of an ... rights law firm.  The investigation is focusing on possible ... by the Board of Directors of THOR for agreeing ... 2015, the Company announced it had reached a definitive ...
(Date:7/27/2015)... 27, 2015  Array BioPharma Inc. (Nasdaq: ... the fourth quarter and full year of ... to discuss those results on Monday, August ... will lead the call.  Date:Monday, ... 507-2598Pass Code: 68380312 Webcast, including Replay and ...
Breaking Medicine Technology:Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 2Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 3Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 4Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 5Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 6Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 7Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 8Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 9Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 10WeissLaw LLP: Thoratec Corporation Acquisition By St. Jude Medical May Not Be In The Best Interest Of THOR Shareholders 2
(Date:7/28/2015)... , ... July 28, 2015 , ... A new study ... Easy Fibromyalgia, Study Says " sheds light on a possible new treatment option for ... two months of regular HBOT sessions, at least five per week, patients experienced a ...
(Date:7/28/2015)... ... 2015 , ... There has been much discussion in Washington, D.C. ... often overlooked is the over 740,000 miles of municipal sewer lines designed ... facilities. According to the American Society of Civil Engineers , the average age ...
(Date:7/28/2015)... ... July 28, 2015 , ... Please join us for the 5th Annual Step ... Center located at Gary Avenue and Lies Road in Carol Stream. All are welcome. ... awareness, and provide education and help to support individuals and families affected by a brain ...
(Date:7/28/2015)... AURORA, Colo. (PRWEB) , ... July 28, 2015 ... ... education provider to offer online RN to BSN cohorts for Geisinger ... The education partnership provides GHS diploma and associate degree prepared nurses with access ...
(Date:7/28/2015)... ... , ... Scientel is thrilled to announce that they been accepted ... McHenry Convention Center in San Jose, Ca. Scientel will be participating as a Silver ... and the industry’s first polymorphic database will address the critical need of efficiently storing ...
Breaking Medicine News(10 mins):Health News:Recovery Specialists Discuss How Oxygen Therapy Can Ease Fibromyalgia 2Health News:Recovery Specialists Discuss How Oxygen Therapy Can Ease Fibromyalgia 3Health News:With an Infrastructure Spending Bill on the Horizon, RestorationEze Discusses the Impact an Aging Sewer System is Having on Homeowners 2Health News:With an Infrastructure Spending Bill on the Horizon, RestorationEze Discusses the Impact an Aging Sewer System is Having on Homeowners 3Health News:5th Annual Step for Hope 5K Run/Walk Event in Carol Stream, IL to Benefit Renowned Brain Aneurysm Foundation 2Health News:American Sentinel University Selected to Provide Online RN to BSN Cohorts to Geisinger Health System 2Health News:American Sentinel University Selected to Provide Online RN to BSN Cohorts to Geisinger Health System 3Health News:American Sentinel University Selected to Provide Online RN to BSN Cohorts to Geisinger Health System 4Health News:Scientel Selected to Present at 2015 NoSQLNow! Conference, San Jose August 18-20 2Health News:Scientel Selected to Present at 2015 NoSQLNow! Conference, San Jose August 18-20 3
... and Amortization Increased ... 3.85% and 2.96%, Respectively, MEXICO CITY, ... "the Group"), one of the leading Mexican,distributors of pharmaceutical products, ... other products,announces its consolidated financial and operating results for the ...
... WASHINGTON, Feb. 26 The following is a,statement ... Tobacco-Free,Kids:, All Nebraska workplaces, including restaurants, bars ... 2009, thanks to,legislation overwhelmingly approved by the Legislature ... Dave Heineman. Governor Heineman and the,Legislature have delivered ...
... Schnitzer West announced today,that one of the country,s most ... in The Shops at The Bravern in downtown Bellevue ... meet the needs of approximately 2,300,Microsoft employees who will ... beginning this fall., DavidBartonGym will offer Barton,s world ...
... Over 200,of MemorialCare,s top leaders will participate in a ... for Humanity of Orange County. The,home will be renovated ... palsy and is confined to a wheelchair. Halls will ... be given a "makeover" with,upgrades throughout., (Photo: ...
... designed to enhance patient acceptance and ... ... a prescription,laxative product that treats acute and chronic constipation, may be ... MiraLAX(R) and generic PEG 3350 products. Marketed in the,U.S. by Cumberland ...
... for His Support of a New ... Playground, LAS ... social service agency, during a ceremonial session of,the Las Vegas City Council meeting. ... playground fundraising,efforts., Mayor Goodman was presented with a plaque of appreciation by ...
Cached Medicine News:Health News:Grupo Casa Saba Announces Fourth Quarter 2007 Results 2Health News:Grupo Casa Saba Announces Fourth Quarter 2007 Results 3Health News:Grupo Casa Saba Announces Fourth Quarter 2007 Results 4Health News:Nebraska's New Smoke-Free Law is Historic Win for Health 2Health News:World-Famous DavidBartonGym Buffs up the Bravern 2Health News:World-Famous DavidBartonGym Buffs up the Bravern 3Health News:MemorialCare Sponsors Habitat for Humanity Santa Ana Home 2Health News:Kristalose(R) Offers Prescription Alternative to MiraLAX(R) and Other PEG 3350 Products 2Health News:Kristalose(R) Offers Prescription Alternative to MiraLAX(R) and Other PEG 3350 Products 3
Indications For Usage: ,Bypass upper airway obstructions, provide long term ventilation, support and/or manage tracheal/bronchial secretions...
Indications For Usage: ,Bypass upper airway obstructions, provide long term ventilation, support and/or manage tracheal/bronchial secretions...
Disposable Cannula Cuffless Tracheostomy Tubes...
Indications For Usage: ,For use with percutaneous tracheotomies...
Medicine Products: